retatrutide approval 2025 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide is the most significant

The methodological problems are considerable: No control group No validated outcome measurement instruments Small sample size Many participants had ligament sprains and tendon issues, conditions that frequently resolve without intervention over that timeframe The authors were affiliated with a clinic supplying the injections, creating a clear conflict of interest A report with this design cannot support causal inference

But you should be aware that your weight loss journey will be much slower than people who have a thyroid

diabteszes retinoptia ll fenn

Unlike semaglutide and liraglutide, tirzepatide is a dual agonist

Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinsons disease